Hepion Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HEPA research report →
Range $70 – $70
Price Chart
About the company
Hepion Pharmaceuticals, Inc. , a U. S.
- CEO
- Sireesh Appajosyula
- IPO
- 2014
- Employees
- 2
- HQ
- Morristown, NJ, US
Get TickerSpark's AI analysis on HEPA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.39M
- P/E
- -0.38
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -1.79
- EV/EBITDA
- 0.77
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -1634.57%
- ROIC
- -106.65%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-4,163,691
- Net Income
- $-8,277,850+37.3%
- EPS
- $-0.88+99.2%
- OCF Growth
- +82.0%
- FCF Growth
- +82.0%
- 52W High
- $0.22
- 52W Low
- $0.03
- 50D MA
- $0.11
- 200D MA
- $0.07
- Beta
- 1.75
- RSI (14)
- 50
- Avg Volume
- 38.34K
No earnings-call transcripts are available for HEPA yet.
- Free Float
- 100.0%
- Shares Outstanding
- 11.64M
- Float Shares
- 11.64M
of shares held by institutions
13 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 82.95K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 23, 26 | Liddy James Gordon | other | 510,000 |
| Oct 23, 26 | Fisher Danina | other | 510,000 |
| Oct 23, 26 | Stetz Gary S. | other | 1,530,000 |
| Oct 23, 26 | LoPriore Vincent S | other | 1,530,000 |
| Oct 23, 26 | Purcell Michael J. | other | 510,000 |
| Oct 23, 26 | Appajosyula Sireesh | other | 1,530,000 |
| Oct 23, 26 | LoPriore Chase | other | 1,530,000 |
| Oct 23, 26 | Stetz Gary S. II | other | 510,000 |
| Oct 6, 26 | Gravitas Collective Corp. | other | 0 |
| Sep 29, 26 | Fisher Danina | buy | 200,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HEPA coverage
Recent articles, reports, and earnings notes.
No research on HEPA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HEPA report →Hepion Pharmaceuticals Receives Positive FDA Response on GV104 in Gambling Disorder, a Condition With No Approved Medication
accessnewswire.com · Oct 19
Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update
accessnewswire.com · Oct 14
MusclePharm (OTCMKTS:MSLP) & Hepion Pharmaceuticals (NASDAQ:HEPA) Critical Contrast
defenseworld.net · Apr 3
Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma
globenewswire.com · Mar 3
Hepion Pharmaceuticals Successfully Completes Application to the OTCQB
globenewswire.com · Jun 25
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
globenewswire.com · May 12
Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC
globenewswire.com · May 7
Hepion Pharmaceuticals Announces Reverse Stock Split
globenewswire.com · Mar 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.